Australia's Imugene climbs on FDA fast-track designation for lymphoma drug

Shares of Imugene IMU.AX rise 4.3% to A$0.0365, their highest levels since February 28

The pharmaceutical co says the US Food and Drug Administration (FDA) has granted fast-track designation to its allogeneic CAR T-cell therapy, azer-cel

Drug used for the treatment of relapsed or refractory diffuse large B-cell lymphoma - co

Over 27 million shares change hands, vs the 30-day average of 18.3 million

Stock marks its biggest intraday gain since February 14